"Karyopherins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of proteins involved in NUCLEOCYTOPLASMIC TRANSPORT. Karyopherins are heteromeric molecules composed two major types of components, ALPHA KARYOPHERINS and BETA KARYOPHERINS, that function together to transport molecules through the NUCLEAR PORE COMPLEX. Several other proteins such as RAN GTP BINDING PROTEIN and CELLULAR APOPTOSIS SUSCEPTIBILITY PROTEIN bind to karyopherins and participate in the transport process.
| Descriptor ID |
D028884
|
| MeSH Number(s) |
D12.776.157.530.750.500 D12.776.543.585.750.500 D12.776.660.502
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Karyopherins".
Below are MeSH descriptors whose meaning is more specific than "Karyopherins".
This graph shows the total number of publications written about "Karyopherins" by people in this website by year, and whether "Karyopherins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 2 | 0 | 2 |
| 2000 | 1 | 0 | 1 |
| 2006 | 2 | 1 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 3 | 4 |
| 2019 | 0 | 2 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Karyopherins" by people in Profiles.
-
Take your mother's ferry: preimplantation embryo development requires maternal karyopherins for nuclear transport. J Clin Invest. 2023 01 17; 133(2).
-
Exportin(g) precision oncology beyond genomics with XPO1 inhibition. Med. 2022 11 11; 3(11):730-732.
-
Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC). Lung Cancer. 2021 10; 160:92-98.
-
TNPO2 variants associate with human developmental delays, neurologic deficits, and dysmorphic features and alter TNPO2 activity in Drosophila. Am J Hum Genet. 2021 09 02; 108(9):1669-1691.
-
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. Invest New Drugs. 2021 10; 39(5):1357-1365.
-
A noncanonical microRNA derived from the snaR-A noncoding RNA targets a metastasis inhibitor. RNA. 2021 06; 27(6):694-709.
-
Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. Gastroenterology. 2021 07; 161(1):196-210.
-
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. J Hematol Oncol. 2020 11 04; 13(1):148.
-
Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma. J Cutan Pathol. 2020 Oct; 47(10):954-959.
-
NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors. Mol Cancer Ther. 2020 08; 19(8):1727-1735.